For research use only. Not for therapeutic Use.
Ceforanide（Cat No.:R023161）is a second-generation cephalosporin antibiotic with a broad spectrum of activity, particularly effective against Gram-positive and some Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Known for its long half-life, ceforanide allows for less frequent dosing, which improves patient compliance, especially in treating respiratory, urinary, and skin infections. Its high stability against certain beta-lactamase enzymes enhances its efficacy against resistant strains. Ceforanide’s pharmacokinetic profile and safety make it a valuable option for treating moderate to severe bacterial infections.
| Catalog Number | R023161 |
| CAS Number | 60925-61-3 |
| Synonyms | (6R,7R)-7-[[[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-trans)-7-[[[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[[1-(carboxymethyl)-1H-tetrazol- |
| Molecular Formula | C20H21N7O6S2 |
| Purity | ≥95% |
| Target | Bacterial |
| Storage | -20°C |
| IUPAC Name | (6R,7R)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1 |
| InChIKey | SLAYUXIURFNXPG-CRAIPNDOSA-N |
| SMILES | C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3CN)C(=O)O)CSC4=NN=NN4CC(=O)O |
| Reference | </br>1:Spectrophotometric determination of certain cephalosporins using molybdophosphoric acid. Part II. Determination of cefadroxil, cefapirin, ceforanide and cefuroxime. Issopoulos PB.Analyst. 1989 Feb;114(2):237-9. PMID: 2712321 </br>2:Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. Crowle AJ, Sbarbaro JA, May MH.Tubercle. 1988 Mar;69(1):15-25. PMID: 3140456 </br>3:Plasma and tissue concentrations of ceforanide and cefazolin in women undergoing hysterectomy. Souney PF, Fisher S, Tuomala RE, Polk BF, Simpson C.Chemotherapy. 1988;34(3):185-90. PMID: 3416659 </br>4:Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Campoli-Richards DM, Lackner TE, Monk JP.Drugs. 1987 Oct;34(4):411-37. Review. PMID: 3315624 </br>5:Treatment of scleroma with ceforanide. Cone LA, Barton SM, Woodard DR.Arch Otolaryngol Head Neck Surg. 1987 Apr;113(4):374-6. PMID: 3814386 </br>6:Comparison of ceforanide and cephalothin prophylaxis in patients undergoing total joint arthroplasty. Soave R, Hirsch JC, Salvati EA, Brause BD, Roberts RB.Orthopedics. 1986 Dec;9(12):1657-60. PMID: 3547369 </br>7:Ceforanide pharmacokinetics in haemodialysis: the effect of ultrafiltration. Lanao JM, de Prada CR, Dominguez-Gil A, Tabernero JM, Martín J, Gómez JR.Biopharm Drug Dispos. 1986 Jul-Aug;7(4):335-46. PMID: 3768489 </br>8:Comment: Ceforanide half-life. Farchione LA.Drug Intell Clin Pharm. 1986 Mar;20(3):234. No abstract available. PMID: 3956386 </br>9:Efficacy and safety of ceforanide. Farchione LA.J Pediatr. 1986 Jan;108(1):162-3. No abstract available. PMID: 3944688 </br>10:Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum. Barry AL, Jones RN, Packer RR.Antimicrob Agents Chemother. 1986 Jan;29(1):147-9. PMID: 3729326 Free PMC Article |
